Last updated: February 27, 2026
What Is NDC 57237-0232?
NDC 57237-0232 corresponds to Ribociclib (Kisqali), a selective CDK4/6 inhibitor approved for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The drug is marketed by Novartis. It received approval from the FDA in March 2017 for combination use with hormonal therapy and later expanded indications.
Current Market Overview
Market Size & Adoption:
- The global breast cancer drug market was valued at approximately USD 7.1 billion in 2022.
- CDK4/6 inhibitors accounted for over 50% of this market segment, driven by the approval and adoption of drugs like Ribociclib, Palbociclib, and Abemaciclib.
- As of 2023, Ribociclib holds a significant market share, estimated at around 24%, given its competitive positioning and clinical profile.
Key Competitors:
| Drug |
Market Share (2023) |
Price per Treatment Cycle |
Approval Year |
Indications |
| Ribociclib (Kisqali) |
24% |
USD 10,000–12,000 |
2017 |
HR+, HER2- advanced breast cancer |
| Palbociclib (Ibrance) |
42% |
USD 11,000–13,000 |
2015 |
HR+, HER2- advanced breast cancer |
| Abemaciclib (Verzenio) |
30% |
USD 9,000–11,000 |
2017 |
HR+, HER2- advanced breast cancer |
Market Drivers:
- Increasing incidence of breast cancer, particularly hormone receptor-positive subtypes.
- Growing adoption of CDK4/6 inhibitors as standard of care.
- Expanded indications and combination regimens.
- Extending treatment lines and improving survival outcomes.
Pricing Trends and Cost Factors
Pricing Dynamics:
- Listed price per 28-day cycle: USD 10,000–12,000.
- Prices vary based on formulary, insurance coverage, and generic entry.
- Price increases observed in 2020-2022 due to manufacturing costs and inflation adjustments.
- Generic versions are not yet available for Ribociclib; patent exclusivity extends into the late 2020s.
Reimbursement & Payer Policies:
- Coverage aligns with national and private insurance policies for breast cancer treatments.
- Cost-effectiveness analyses cited in some protocols favor Ribociclib due to improved progression-free survival (PFS).
Price Projections Through 2030
Assumptions & Methodology:
- Continued patent protection until 2028.
- Market growth driven by increasing breast cancer incidence rates: projected CAGR of 4% in the global market.
- Entry of generics expected post-2028, potentially reducing prices by 40–60%.
- Future pricing models incorporate inflation, market expansion, and competitive pressures.
Price Trajectory (USD):
| Year |
Estimated Price per Cycle |
Rationale |
| 2023 |
USD 10,000–12,000 |
Current stabilized pricing |
| 2025 |
USD 9,800–11,600 |
Slight reduction due to market competition potential |
| 2027 |
USD 9,500–11,000 |
Pre-generic entry, potential discounts for volume sales |
| 2028 |
USD 8,000–10,000 |
Patent expiry approaches, generic entry begins |
| 2030 |
USD 4,000–6,000 |
Post-generic market, significant price erosion |
Key Influences on Price Dynamics:
- Patent expiration around 2028.
- Generic development triggered by patent challenges and biosimilars.
- Regulatory approvals expanding indications or restricting use could impact volume and pricing.
- Insurance reimbursement policies impacting net pricing.
Strategic Considerations for Stakeholders
- Pharmaceutical Firms: Should invest in lifecycle management strategies, including new indications and combination therapies.
- Insurers: May push for discounts, tier management, and biosimilar inclusion post-2028.
- Investors: Opportunities exist in early generic development post-patent expiry; anticipate a potential price drop of roughly 50–60%.
Summary of Factors Influencing Market and Prices
- Incidence & prevalence growth.
- Competitive landscape shifts with generics.
- Regulatory and reimbursement environment.
- Technological advances and biosimilar development.
- Clinical trial data affecting overall adoption.
Key Takeaways
- NDC 57237-0232 (Ribociclib) is a leading CDK4/6 inhibitor with significant market share in breast cancer therapy.
- Current pricing remains USD 10,000–12,000 per 28-day cycle; prices could decline post-patent expiry in 2028.
- Market growth driven by rising breast cancer cases and expanded indications.
- Generic entry expected to reduce prices by up to 60% by 2030.
- Strategic focus on lifecycle management and biosimilars will shape future market dynamics.
FAQs
1. What factors could accelerate the generic entry for Ribociclib?
Patent challenges, patent expiry in 2028, and advancements in biosimilar development could lead to earlier generic drug availability.
2. How does Ribociclib compare to other CDK4/6 inhibitors in price?
It is roughly comparable, with a typical cycle cost around USD 10,000–12,000, slightly lower than Palbociclib but similar to Abemaciclib.
3. What is the main driver behind the rising market for CDK4/6 inhibitors?
The increasing incidence of hormone receptor-positive breast cancer and proven clinical benefits sustain high adoption.
4. How might reimbursement policies influence future pricing?
Payer pressure for discounts and formulary restrictions could reduce net prices, especially after patent expiry.
5. When are biosimilars for Ribociclib expected to enter the market?
Biosimilars are unlikely before 2028, the expiration date of the current patent, after which price reductions are anticipated.
References
[1] GlobalData. (2023). Breast Cancer Market Overview.
[2] IQVIA. (2023). Oncology Revenue & Market Share Analysis.
[3] U.S. Food & Drug Administration. (2017). FDA Approval for Ribociclib.
[4] WHO. (2022). Global Cancer Incidence and Trends.
[5] Novartis. (2023). Kisqali Product Information & Market Data.
